RxDoctor Payments Data

Kecia Ford

Internal Medicine · East Meadow, NYNPI 1063741023

Payments from drug & device makers

$7,607in general payments, 2019–2025

Across 199 payments — averaging $38.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$1K
  • Amgen$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$791
  • Dexcom, Inc.$783
  • AbbVie$735
  • AstraZeneca$631
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$7,39597%
  • Education$931%
  • Gifts$1192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,607 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
LofenaDiclofenac Potassium36$212,464
JardianceEmpagliflozin136$156,604
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate48$120,938
JanuviaSitagliptin Phosphate96$117,523
KerendiaFinerenone64$86,281
AfrezzaInsulin Regular, Human34$61,577
RybelsusSemaglutide45$50,078
Diclofenac Potassium26$48,412
OzempicSemaglutide40$40,220
LinzessLinaclotide44$36,129
Diclofenac Sodium89$27,641
JanumetSitagliptin Phos/Metformin Hcl27$27,010
TradjentaLinagliptin25$26,984
Nurtec OdtRimegepant Sulfate14$26,877
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$44$144,533123 claims
Novo NordiskRybelsus, Ozempic$539$90,29885 claims
BayerKerendia$191$86,28164 claims
Mannkind CorporationAfrezza$193$61,57734 claims
PfizerNurtec Odt, Eliquis$145$42,15830 claims
AbbVieLinzess$735$36,12944 claims
GSKTrelegy Ellipta, Shingrix$178$22,38141 claims
AstraZenecaBrilinta$631$11,28422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →